247 research outputs found

    Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer

    Get PDF
    Tyrosine kinase inhibitors (TKIs) are molecules that compete with ATP on tyrosine kinase receptors (TKRs), blocking tyrosine kinase (TK) activation and then oncogenic pathways; they have been studied, and some of them are right approved for the treatment of many types of cancer. Among TKIs, one of the most explored chemical template is the pyrazolo[3,4-d]pyrimidine (PP) heterocyclic core, which proved to be a useful scaffold for the obtainment of effective compounds. Actually, derivatives belonging to this structural class show a large spectrum of activity, thus standing out as multi-target agents. Different PP compounds have been shown to act as: a) ABL inhibitors and antiproliferative agents against human leukemia cell lines; b) Src kinase inhibitors in neuroblastoma, medulloblastoma and osteosarcoma; c) Phospholipase D inhibitors in different neoplasias; d) Urokinase plasminogen activator inhibitors, in breast cancer. In thyroid cancer (TC), PP1 and PP2 (inhibitors of RET, Hck, lck, and fynT kinases, and a good inhibitor of c-Src and platelet-derived growth factor receptor) showed antineoplastic actvity in human papillary TC cell lines that carry spontaneous RET/PTC1 rearrangements. More recently, new derivatives, (R)-1-phenethyl-N-(1-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4- amine, namely, CLM3 and CLM29, have been demonstrated to exert a multiple signal transduction inhibition (including the RET-TK, BRAF, EGFR, and with antiangiogenic activity), showing antineoplastic activity, in vitro and in vivo, in papillary dedifferentiated, medullary and anaplastic TC. These data have shown the antineoplastic activity of PP in different neoplasias, opening the way to a future clinical evaluation in human cancers

    Status of the Local Monitor and Control System of SKA Dishes

    Get PDF
    The Square Kilometer Array (SKA) project aims at building the world's largest radio observatory to observe the radio sky with unprecedented sensitivity and collecting area. In the SKA1 phase of the project, two dish arrays are to be built, one in South Africa (SKA1-Mid) and the other in Western Australia (SKA1-Survey). Each antenna will be provided with a local monitor and control system, enabling remote operations to engineers and to the Telescope Manager system. In this paper we present the current status of the software system being designed to monitor and control the dish subsystem. An overview of the dish instrumentation is reported, along with details concerning the software architecture, functional interfaces, prototyping and the evaluated technologies

    The design of the local monitor and control system of SKA dishes

    Get PDF
    The Square Kilometer Array (SKA) project aims at building the world's largest radio observatory to observe the sky with unprecedented sensitivity and collecting area. In the first phase of the project (SKA1), an array of dishes, SKA1-MID, will be built in South Africa. It will consist of 133 15m-dishes, which will include the MeerKAT array, for the 0.350-20 GHz frequency band observations. Each antenna will be provided with a local monitor and control system (LMC), enabling operations both to the Telescope Manager remote system, and to the engineers and maintenance staff; it provides different environment for the telescope control (positioning, pointing, observational bands), metadata collection for monitoring and database storaging, operational modes and functional states management for all the telescope capabilities. In this paper we present the LMC software architecture designed for the detailed design phase (DD), where we describe functional and physical interfaces with monitored and controlled sub-elements, and highlight the data flow between each LMC modules and its sub-element controllers from one side, and Telescope Manager on the other side. We also describe the complete Product Breakdown Structure (PBS) created in order to optimize resources allocation in terms of calculus and memory, able to perform required task for each element according to the proper requirements. Among them, time response and system reliability are the most important, considering the complexity of SKA dish network and its isolated placement. Performances obtained by software implementation using TANGO framework will be discussed, matching them with technical requirements derived by SKA science drivers

    A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol

    Get PDF
    ORTHOUNION is a multicentre, open, comparative, three-arm, randomized clinical trial (EudraCT number 2015-000431-32) to compare the efficacy, at one and two years, of autologous human bone marrow-derived expanded mesenchymal stromal cell (hBM-MSC) treatments versus iliac crest autograft (ICA) to enhance bone healing in patients with diaphyseal and/or metaphysodiaphyseal fracture (femur, tibia, and humerus) status of atrophic or oligotrophic nonunion (more than 9 months after the acute fracture, including recalcitrant cases after failed treatments). The primary objective is to determine if the treatment with hBM-MSCs combined with biomaterial is superior to ICA in obtaining bone healing. If confirmed, a secondary objective is set to determine if the dose of 100 × 106 hBM-MSCs is noninferior to that of 200 × 106 hBM-MSCs. The participants (n = 108) will be randomly assigned to either the experimental low dose (n = 36), the experimental high dose (n = 36), or the comparator arm (n = 36) using a central randomization service. The trial will be conducted in 20 clinical centres in Spain, France, Germany, and Italy under the same clinical protocol. The confirmation of superiority for the proposed ATMP in nonunions may foster the future of bone regenerative medicine in this indication. On the contrary, absence of superiority may underline its limitations in clinical use

    Correction to: Two years later: Is the SARS-CoV-2 pandemic still having an impact on emergency surgery? An international cross-sectional survey among WSES members

    Get PDF
    Background: The SARS-CoV-2 pandemic is still ongoing and a major challenge for health care services worldwide. In the first WSES COVID-19 emergency surgery survey, a strong negative impact on emergency surgery (ES) had been described already early in the pandemic situation. However, the knowledge is limited about current effects of the pandemic on patient flow through emergency rooms, daily routine and decision making in ES as well as their changes over time during the last two pandemic years. This second WSES COVID-19 emergency surgery survey investigates the impact of the SARS-CoV-2 pandemic on ES during the course of the pandemic. Methods: A web survey had been distributed to medical specialists in ES during a four-week period from January 2022, investigating the impact of the pandemic on patients and septic diseases both requiring ES, structural problems due to the pandemic and time-to-intervention in ES routine. Results: 367 collaborators from 59 countries responded to the survey. The majority indicated that the pandemic still significantly impacts on treatment and outcome of surgical emergency patients (83.1% and 78.5%, respectively). As reasons, the collaborators reported decreased case load in ES (44.7%), but patients presenting with more prolonged and severe diseases, especially concerning perforated appendicitis (62.1%) and diverticulitis (57.5%). Otherwise, approximately 50% of the participants still observe a delay in time-to-intervention in ES compared with the situation before the pandemic. Relevant causes leading to enlarged time-to-intervention in ES during the pandemic are persistent problems with in-hospital logistics, lacks in medical staff as well as operating room and intensive care capacities during the pandemic. This leads not only to the need for triage or transferring of ES patients to other hospitals, reported by 64.0% and 48.8% of the collaborators, respectively, but also to paradigm shifts in treatment modalities to non-operative approaches reported by 67.3% of the participants, especially in uncomplicated appendicitis, cholecystitis and multiple-recurrent diverticulitis. Conclusions: The SARS-CoV-2 pandemic still significantly impacts on care and outcome of patients in ES. Well-known problems with in-hospital logistics are not sufficiently resolved by now; however, medical staff shortages and reduced capacities have been dramatically aggravated over last two pandemic years

    Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

    Get PDF
    Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

    Observation of the B0 → ρ0ρ0 decay from an amplitude analysis of B0 → (π+π−)(π+π−) decays

    Get PDF
    Proton–proton collision data recorded in 2011 and 2012 by the LHCb experiment, corresponding to an integrated luminosity of 3.0 fb−1 , are analysed to search for the charmless B0→ρ0ρ0 decay. More than 600 B0→(π+π−)(π+π−) signal decays are selected and used to perform an amplitude analysis, under the assumption of no CP violation in the decay, from which the B0→ρ0ρ0 decay is observed for the first time with 7.1 standard deviations significance. The fraction of B0→ρ0ρ0 decays yielding a longitudinally polarised final state is measured to be fL=0.745−0.058+0.048(stat)±0.034(syst) . The B0→ρ0ρ0 branching fraction, using the B0→ϕK⁎(892)0 decay as reference, is also reported as B(B0→ρ0ρ0)=(0.94±0.17(stat)±0.09(syst)±0.06(BF))×10−6

    Study of the rare B-s(0) and B-0 decays into the pi(+) pi(-) mu(+) mu(-) final state

    Get PDF
    A search for the rare decays Bs0π+πμ+μB_s^0 \to \pi^+\pi^-\mu^+\mu^- and B0π+πμ+μB^0 \to \pi^+\pi^-\mu^+\mu^- is performed in a data set corresponding to an integrated luminosity of 3.0 fb1^{-1} collected by the LHCb detector in proton-proton collisions at centre-of-mass energies of 7 and 8 TeV. Decay candidates with pion pairs that have invariant mass in the range 0.5-1.3 GeV/c2c^2 and with muon pairs that do not originate from a resonance are considered. The first observation of the decay Bs0π+πμ+μB_s^0 \to \pi^+\pi^-\mu^+\mu^- and the first evidence of the decay B0π+πμ+μB^0 \to \pi^+\pi^-\mu^+\mu^- are obtained and the branching fractions are measured to be B(Bs0π+πμ+μ)=(8.6±1.5(stat)±0.7(syst)±0.7(norm))×108\mathcal{B}(B_s^0 \to \pi^+\pi^-\mu^+\mu^-)=(8.6\pm 1.5\,({\rm stat}) \pm 0.7\,({\rm syst})\pm 0.7\,({\rm norm}))\times 10^{-8} and B(B0π+πμ+μ)=(2.11±0.51(stat)±0.15(syst)±0.16(norm))×108\mathcal{B}(B^0 \to \pi^+\pi^-\mu^+\mu^-)=(2.11\pm 0.51\,({\rm stat}) \pm 0.15\,({\rm syst})\pm 0.16\,({\rm norm}) )\times 10^{-8}, where the third uncertainty is due to the branching fraction of the decay B0J/ψ(μ+μ)K(890)0(K+π)B^0\to J/\psi(\to \mu^+\mu^-)K^*(890)^0(\to K^+\pi^-), used as a normalisation.A search for the rare decays Bs0→π+π−μ+μ− and B0→π+π−μ+μ− is performed in a data set corresponding to an integrated luminosity of 3.0 fb−1 collected by the LHCb detector in proton–proton collisions at centre-of-mass energies of 7 and 8 TeV . Decay candidates with pion pairs that have invariant mass in the range 0.5–1.3 GeV/c2 and with muon pairs that do not originate from a resonance are considered. The first observation of the decay Bs0→π+π−μ+μ− and the first evidence of the decay B0→π+π−μ+μ− are obtained and the branching fractions, restricted to the dipion-mass range considered, are measured to be B(Bs0→π+π−μ+μ−)=(8.6±1.5 (stat)±0.7 (syst)±0.7(norm))×10−8 and B(B0→π+π−μ+μ−)=(2.11±0.51(stat)±0.15(syst)±0.16(norm))×10−8 , where the third uncertainty is due to the branching fraction of the decay B0→J/ψ(→μ+μ−)K⁎(892)0(→K+π−) , used as a normalisation.A search for the rare decays Bs0→π+π−μ+μ− and B0→π+π−μ+μ− is performed in a data set corresponding to an integrated luminosity of 3.0 fb−1 collected by the LHCb detector in proton–proton collisions at centre-of-mass energies of 7 and 8 TeV . Decay candidates with pion pairs that have invariant mass in the range 0.5–1.3 GeV/c2 and with muon pairs that do not originate from a resonance are considered. The first observation of the decay Bs0→π+π−μ+μ− and the first evidence of the decay B0→π+π−μ+μ− are obtained and the branching fractions, restricted to the dipion-mass range considered, are measured to be B(Bs0→π+π−μ+μ−)=(8.6±1.5 (stat)±0.7 (syst)±0.7(norm))×10−8 and B(B0→π+π−μ+μ−)=(2.11±0.51(stat)±0.15(syst)±0.16(norm))×10−8 , where the third uncertainty is due to the branching fraction of the decay B0→J/ψ(→μ+μ−)K⁎(892)0(→K+π−) , used as a normalisation.A search for the rare decays Bs0π+πμ+μB_s^0 \to \pi^+\pi^-\mu^+\mu^- and B0π+πμ+μB^0 \to \pi^+\pi^-\mu^+\mu^- is performed in a data set corresponding to an integrated luminosity of 3.0 fb1^{-1} collected by the LHCb detector in proton-proton collisions at centre-of-mass energies of 7 and 8 TeV. Decay candidates with pion pairs that have invariant mass in the range 0.5-1.3 GeV/c2c^2 and with muon pairs that do not originate from a resonance are considered. The first observation of the decay Bs0π+πμ+μB_s^0 \to \pi^+\pi^-\mu^+\mu^- and the first evidence of the decay B0π+πμ+μB^0 \to \pi^+\pi^-\mu^+\mu^- are obtained and the branching fractions, restricted to the dipion-mass range considered, are measured to be B(Bs0π+πμ+μ)=(8.6±1.5(stat)±0.7(syst)±0.7(norm))×108\mathcal{B}(B_s^0 \to \pi^+\pi^-\mu^+\mu^-)=(8.6\pm 1.5\,({\rm stat}) \pm 0.7\,({\rm syst})\pm 0.7\,({\rm norm}))\times 10^{-8} and B(B0π+πμ+μ)=(2.11±0.51(stat)±0.15(syst)±0.16(norm))×108\mathcal{B}(B^0 \to \pi^+\pi^-\mu^+\mu^-)=(2.11\pm 0.51\,({\rm stat}) \pm 0.15\,({\rm syst})\pm 0.16\,({\rm norm}) )\times 10^{-8}, where the third uncertainty is due to the branching fraction of the decay B0J/ψ(μ+μ)K(890)0(K+π)B^0\to J/\psi(\to \mu^+\mu^-)K^*(890)^0(\to K^+\pi^-), used as a normalisation

    Angular analysis of the B-0 -> K*(0) e(+) e(-) decay in the low-q(2) region

    Get PDF
    An angular analysis of the B0K0e+eB^0 \rightarrow K^{*0} e^+ e^- decay is performed using a data sample, corresponding to an integrated luminosity of 3.0 {\mbox{fb}^{-1}}, collected by the LHCb experiment in pppp collisions at centre-of-mass energies of 7 and 8 TeV during 2011 and 2012. For the first time several observables are measured in the dielectron mass squared (q2q^2) interval between 0.002 and 1.120GeV2 ⁣/c4{\mathrm{\,Ge\kern -0.1em V^2\!/}c^4}. The angular observables FLF_{\mathrm{L}} and ATReA_{\mathrm{T}}^{\mathrm{Re}} which are related to the K0K^{*0} polarisation and to the lepton forward-backward asymmetry, are measured to be FL=0.16±0.06±0.03F_{\mathrm{L}}= 0.16 \pm 0.06 \pm0.03 and ATRe=0.10±0.18±0.05A_{\mathrm{T}}^{\mathrm{Re}} = 0.10 \pm 0.18 \pm 0.05, where the first uncertainty is statistical and the second systematic. The angular observables AT(2)A_{\mathrm{T}}^{(2)} and ATImA_{\mathrm{T}}^{\mathrm{Im}} which are sensitive to the photon polarisation in this q2q^2 range, are found to be AT(2)=0.23±0.23±0.05A_{\mathrm{T}}^{(2)} = -0.23 \pm 0.23 \pm 0.05 and ATIm=0.14±0.22±0.05A_{\mathrm{T}}^{\mathrm{Im}} =0.14 \pm 0.22 \pm 0.05. The results are consistent with Standard Model predictions.An angular analysis of the B0^{0} → K^{*}^{0} e+^{+} e^{−} decay is performed using a data sample, corresponding to an integrated luminosity of 3.0 fb1^{−1}, collected by the LHCb experiment in pp collisions at centre-of-mass energies of 7 and 8 TeV during 2011 and 2012. For the first time several observables are measured in the dielectron mass squared (q2^{2}) interval between 0.002 and 1.120 GeV2^{2} /c4^{4}. The angular observables FL_{L} and ATRe_{T}^{Re} which are related to the K^{*}^{0} polarisation and to the lepton forward-backward asymmetry, are measured to be FL_{L} = 0.16 ± 0.06 ± 0.03 and ATRe_{T}^{Re}  = 0.10 ± 0.18 ± 0.05, where the first uncertainty is statistical and the second systematic. The angular observables AT(2)_{T}^{(2)} and ATIm_{T}^{Im} which are sensitive to the photon polarisation in this q2^{2} range, are found to be AT(2)_{T}^{(2)}  = − 0.23 ± 0.23 ± 0.05 and ATIm_{T}^{Im}  = 0.14 ± 0.22 ± 0.05. The results are consistent with Standard Model predictions.An angular analysis of the B0K0e+eB^0 \rightarrow K^{*0} e^+ e^- decay is performed using a data sample, corresponding to an integrated luminosity of 3.0 {\mbox{fb}^{-1}}, collected by the LHCb experiment in pppp collisions at centre-of-mass energies of 7 and 8 TeV during 2011 and 2012. For the first time several observables are measured in the dielectron mass squared (q2q^2) interval between 0.002 and 1.120GeV2 ⁣/c4{\mathrm{\,Ge\kern -0.1em V^2\!/}c^4}. The angular observables FLF_{\mathrm{L}} and ATReA_{\mathrm{T}}^{\mathrm{Re}} which are related to the K0K^{*0} polarisation and to the lepton forward-backward asymmetry, are measured to be FL=0.16±0.06±0.03F_{\mathrm{L}}= 0.16 \pm 0.06 \pm0.03 and ATRe=0.10±0.18±0.05A_{\mathrm{T}}^{\mathrm{Re}} = 0.10 \pm 0.18 \pm 0.05, where the first uncertainty is statistical and the second systematic. The angular observables AT(2)A_{\mathrm{T}}^{(2)} and ATImA_{\mathrm{T}}^{\mathrm{Im}} which are sensitive to the photon polarisation in this q2q^2 range, are found to be AT(2)=0.23±0.23±0.05A_{\mathrm{T}}^{(2)} = -0.23 \pm 0.23 \pm 0.05 and ATIm=0.14±0.22±0.05A_{\mathrm{T}}^{\mathrm{Im}} =0.14 \pm 0.22 \pm 0.05. The results are consistent with Standard Model predictions
    corecore